首页|PET-CT联合内质网应激标志物检测在非小细胞肺癌化疗效果和预后评估中的应用

PET-CT联合内质网应激标志物检测在非小细胞肺癌化疗效果和预后评估中的应用

扫码查看
目的 探讨正电子发射断层扫描(PET)/CT联合内质网应激(ERS)标志物在非小细胞肺癌(NSCLC)化疗效果和预后评估中的应用.方法 选取 2017 年 9 月至 2022 年 6 月于唐山市人民医院放化一科病理诊断为NSCLC的 84 例患者的临床资料进行回顾性分析.通过 PET/CT 定量评估氟代氟脱氧葡萄糖(18F-FDG)最大摄取(SUVmax),用酶联免疫吸附法测定血清Tribbles 同源蛋白 3(TRB3)、萄糖调节蛋白 78(GRP78)和 C/EBP 同源蛋白(CHOP)水平.评估 SUVmax和各 ERS标志物的相关性以及各指标和治疗反应的相关性.通过受试者工作特征曲线(ROC)获得 SUVmax和 ERS标志物用于识别治疗反应者的最佳临界值.结果 入选 NSCLC患者的 CHOP(r=-0.284,P=0.007)和TRB3(r=0.387,P=0.005)与 SUVmax显示出明显的相关性,而 GRP78 与 SUVmax没有明显的相关性(r=0.086,P=0.443).84 名 NSCLC 患者中 CR、PR、SD 和 PD 例数分别为 2 例(2.4%)、43 例(51.2%)、34 例(40.5%)和 5 例(6.0%).多因素分析表示 SUVmax(OR:1.217,95%CI:1.090~1.525,P=0.002)、CHOP(OR:0.140,95%CI:0.062~0.454,P<0.001)和临床分期(OR:1.283,95%CI:1.112~1.718,P=0.009)是治疗反应的独立预测因素.在 SUV_CHOP 评分系统中得分为 0 分、1 分和 2 分的患者客观缓解率分别为 90%(18/20)、60.6%(20/33)、22.6%(7/31)(P<0.001),中位无进展生存期(PFS)分别为 18.9、13.6 和 10.6 个月(P<0.001),和中位总生存期(OS)分别为 28.3、19.4 和 13.4 个月(P<0.001).结论 接受一线化疗的Ⅲ-Ⅳ期 NSCLC患者中,治疗前 SUVmax和CHOP是临床化疗反应和预后的独立预测因素,两者联合建立的 SUV_CHOP评分系统对化疗反应和预后有较好的预测价值.
Application of PET-CT Combined with Endoplasmic Reticulum Stress Marker Detection in Evaluation of Chemotherapeutic Efficacy and Prognosis of Non-Small Cell Lung Cancer
Objective To explore the application of PET-CT combined with endoplasmic retic-ulum stress(ERS)marker detection in the evaluation of chemotherapeutic efficacy and prognosis of non-small cell lung cancer(NSCLC).Methods Clinical data of 84 patients who were pathologi-cally diagnosed with NSCLC by Department of Radiotherapy,Tangshan People's Hospital,from September 2017 to June 2022 were analyzed retrospectively.The maximum 18 F-fluorodeoxyglu-cose(18 F-FDG)uptake(SUVmax)was quantitatively evaluated by PET/CT.Serum levels of trib-bles homologous protein 3(TRB3),glucose regulatory protein 78(GRP78)and C/EBP homolo-gous protein(CHOP)were determined by ELISA.The correlation between SUVmax and ERS markers and the correlation between the markers and therapeutic response were evaluated.In ad-dition,the optimal cutoff values of SUVmax and ERS markers for identifying therapeutic response were obtained using the receiver operating characteristic(ROC)curve.Results The SUVmax was obviously correlated with the levels of CHOP(r=-0.284,P=0.007)and TRB3(r=0.387,P= 0.005),but was not related to the level of GRP78(r=0.086,P=0.443).Among the 84 NSCLC patients,CR,PR,SD and PD occurred in 2(2.4%),43(51.2%),34(40.5%)and 5(6.0%),respec-tively.Multivariate analysis showed that SUVmax(OR:1.217;95%CI:1.090-1.525;P =0.002),CHOP(OR:0.140;95%CI:0.062-0.454;P<0.001)and clinical stage(OR:1.283;95%CI:1.112-1.718;P=0.009)were the independent predictors of treatment response.With the SUV_CHOP scoring system,the objective remission rates of patients with scores of 0,1 and 2 were 90%(18/20),60.6%(20/33)and 22.6%(7/31),the median progression-free survivals were 18.9,13.6 and 10.6,and the median overall survivals were 28.3,19.4 and 13.4 months,respectively(P<0.001).Conclusion In stage Ⅲ-Ⅳ NSCLC patients treated with first-line chemotherapy,SUVmax and CHOP are independent predictors of therapeutic response and prognosis,and the SUV_CHOP scoring system established by their combination has a good predictive value for therapeutic re-sponse and prognosis.

PET/CTendoplasmic reticulum stressnon-small cell lung cancerclinical tumor reactionprognosis

陈婧姼、邢影、杨俊泉

展开 >

唐山市人民医院(唐山市肿瘤医院)放化一科,河北 唐山 063000

PET/CT 内质网应激 非小细胞肺癌 临床肿瘤反应 预后

河北省医学科学研究课题计划

20192395

2024

南昌大学学报(医学版)
南昌大学

南昌大学学报(医学版)

CSTPCD
影响因子:1.008
ISSN:2095-4727
年,卷(期):2024.64(1)
  • 3